Cytomel and Nexavar

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

When used for the treatment of thyroid cancer, SORAfenib may alter the effectiveness of liothyronine. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Talk to your doctor or pharmacist if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Sorafenib impairs exogenous thyroid suppression in differentiated thyroid carcinoma (DTC). In a study of patients with DTC, 99% of patients had a baseline thyroid stimulating hormone (TSH) level less than 0.5 mU/L. During treatment, elevation of TSH level above 0.5 mU/L was observed in 41% of sorafenib-treated patients versus 16% of placebo-treated patients. For patients with impaired TSH suppression while receiving sorafenib, the median maximal TSH was 1.6 mU/L, with 25% exhibiting TSH levels greater than 4.4 mU/L.

MANAGEMENT: TSH levels should be monitored monthly during sorafenib treatment for differentiated thyroid carcinoma, and the dosage of thyroid replacement medication adjusted as necessary.

Cytomel

Generic Name: liothyronine

Brand name: Cytomel, Triostat

Synonyms: n.a.

What is Cytomel?

Nexavar

Generic Name: sorafenib

Brand name: Nexavar

Synonyms: n.a.

What is Nexavar?